Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
allergic bronchopulmonary aspergillosis in internal medicine
Original title: “[Allergic bronchopulmonary aspergillosis in internal medicine].”
t cell lymphoproliferative disorders epidemiology pathophysiology and diagnosis
Original title: “[T-cell lymphoproliferative disorders: Epidemiology, pathophysiology, and diagnosis].”
safety of inhaled levofloxacin in people with cystic fibrosis data from uk and german registries
Original title: “Safety of inhaled levofloxacin in people with cystic fibrosis: Data from UK and German Registries.”
predictive atlas of disease onset from retinal fundus photographs a modelling study using data from population based cohorts
Original title: “A predictive atlas of disease onset from retinal fundus photographs: a modelling study using data from population-based cohorts.”
transforming cisplatin into targeted photothermal chemotherapeutics through the platinum phosphate coordination within a hyaluronan nanogel
Original title: “Transforming cisplatin into targeted photothermal chemotherapeutics through the platinum-phosphate coordination within a hyaluronan nanogel.”
financial burden in adults with chronic illness in switzerland a secondary analysis of qualitative interviews using natural language processing and topic modeling
Original title: “Financial Burden in Adults With Chronic Illness in Switzerland: A Secondary Analysis of Qualitative Interviews Using Natural Language Processing and Topic Modeling.”
transition and transfer from pediatrics to adult medicine
Original title: “[Transition and transfer from pediatrics to adult medicine].”
pregnancy and lactation associated osteoporosis a systematic review
Original title: “Pregnancy and Lactation Associated Osteoporosis: A Systematic Review.”
renal outcomes of glp 1 receptor agonists and tirzepatide across ckd stages and metabolic phenotypes type 2 diabetes and or overweight obesity a scoping review
Original title: “Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review.”
primary biliary cholangitis and prognostic models reply
Original title: “Primary Biliary Cholangitis and Prognostic Models-Reply.”
rupture of a nonaneurysmal left sinus of valsalva into the pericardium
Original title: “Rupture of a Nonaneurysmal Left Sinus of Valsalva Into the Pericardium.”
temporal trends in hepatic steatosis and its risk factors among young adults a comparative cohort study
Original title: “Temporal trends in hepatic steatosis and its risk factors among young adults: A comparative cohort study.”
gastric synovial sarcoma a case report and review of literature
Original title: “Gastric Synovial Sarcoma: A Case Report and Review of Literature.”
profound biotinidase deficiency as a treatable cause of pediatric diffuse leukoencephalopathy and diffusion restriction
Original title: “Profound Biotinidase Deficiency as a Treatable Cause of Pediatric Diffuse Leukoencephalopathy and Diffusion Restriction.”
diagnostic delay in mycosis fungoides insights from china s first multicentre registry of 305 patients
Original title: “Diagnostic delay in mycosis fungoides: Insights from China's first multicentre registry of 305 patients.”
intellectual disability causing mutations in kif11 impair microtubule dynamics and dendritic arborization
Original title: “Intellectual disability-causing mutations in KIF11 impair microtubule dynamics and dendritic arborization.”
/PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and Viralgen, a leading... NEW YORK and SAN SEBASTIÁN, Spain, March 17, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, today announced a strategic manufacturing collaboration to support gene therapy programs using Apertura's TfR1 CapX, a novel AAV capsid that targets human Transferrin Receptor 1 (hTfR1) to cross the blood-brain barrier. This established transport mechanism has a strong clinical track record in pediatric and geriatric populations, expanding its potential to treat serious neurological and genetic diseases. Apertura has licensed its next-generation capsids to multiple partners, with programs expected to enter clinical trials this year and next year. Founded in 2021 on technology from the Broad Institute and supported by Deerfield Management Company, Apertura Gene Therapy is headquartered in New York City. Viralgen is a leading Contract Development and Manufacturing Organization (CDMO) specializing exclusively in adeno-associated virus (AAV)-based gene therapies. Founded in 2017 as a subsidiary of AskBio, Inc. within the Bayer AG group, Viralgen delivers end-to-end support from early development to large-scale commercial manufacturing. Leveraging their proprietary Pro10™ suspension cell line and Aava™ manufacturing platform, Viralgen achieves industry-leading, high-yield, scalable manufacturing across all AAV serotypes. "We believe having a well-characterized production framework in place enables gene therapy programs to progress more efficiently toward clinical development and supports the development of more effective and scalable gene therapies," said Jimmy Vanhove, Chief Executive Officer at Viralgen. Viralgen has scaled up TfR1 CapX manufacturing and is ready to support research and clinical development programs. The established AAV platform manufacturing process has been successfully deployed across more than 1.500 batches. Viralgen provides CMC services, including essential starting materials such as Master Cell Bank (MCB) creation and plasmid supply as part of its integrated AAV manufacturing services.
Original title: “Apertura Gene Therapy and Viralgen Announce Strategic Collaboration to Manufacture TfR1 CapX, a Next-Generation Capsid for Gene Therapies Designed to Treat Central Nervous System Diseases”
autopsy case with fragile x associated tremor ataxia syndrome presenting intranuclear inclusion bodies mainly in the limbic system
Original title: “An Autopsy Case With Fragile X-Associated Tremor/Ataxia Syndrome Presenting Intranuclear Inclusion Bodies Mainly in the Limbic System.”
deficient cardiolipin remodelling alters muscle fibre composition and neuromuscular connectivity in barth syndrome
Original title: “Deficient Cardiolipin Remodelling Alters Muscle Fibre Composition and Neuromuscular Connectivity in Barth Syndrome.”